Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?

McCartney A, Di Leo A, Malorni L.

Oncotarget. 2018 Sep 25;9(75):34031-34032. doi: 10.18632/oncotarget.26133. eCollection 2018 Sep 25. No abstract available.

2.

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.

Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, DI Leo A, Biganzoli L.

Anticancer Res. 2018 Aug;38(8):4839-4845. doi: 10.21873/anticanres.12795.

PMID:
30061257
3.

The role of abemaciclib in treatment of advanced breast cancer.

McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 May 31;10:1758835918776925. doi: 10.1177/1758835918776925. eCollection 2018. Review.

4.

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A.

Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214.

PMID:
29893790
5.

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumüller M, Guarducci C, Boccalini G, Gabellini S, Migliaccio I, Di Leo A, Pestrin M, Malorni L.

Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700. eCollection 2018 Mar 27.

6.

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.

Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L.

Breast Cancer Res Treat. 2018 Jul;170(2):329-341. doi: 10.1007/s10549-018-4766-2. Epub 2018 Mar 22.

PMID:
29564743
7.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

Di Leo A, Jerusalem G, Torres R, Verhoeven D, Pendergrass K, Malorni L, Lichfield J, Martin M.

Breast. 2018 Apr;38:144-149. doi: 10.1016/j.breast.2017.12.016. Epub 2018 Jan 8.

PMID:
29324303
8.

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

Guarducci C, Bonechi M, Boccalini G, Benelli M, Risi E, Di Leo A, Malorni L, Migliaccio I.

Breast Care (Basel). 2017 Oct;12(5):304-308. doi: 10.1159/000484167. Epub 2017 Oct 27. Review.

9.

Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

Malorni L, Biganzoli L.

Breast Care (Basel). 2017 Oct;12(5):288-289. doi: 10.1159/000484259. Epub 2017 Oct 25. No abstract available.

10.

Exposure to sub-10nm particles emitted from a biodiesel-fueled diesel engine: In vitro toxicity and inflammatory potential.

Malorni L, Guida V, Sirignano M, Genovese G, Petrarca C, Pedata P.

Toxicol Lett. 2017 Mar 15;270:51-61. doi: 10.1016/j.toxlet.2017.02.009. Epub 2017 Feb 9.

PMID:
28189646
11.

TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.

Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L.

Clin Cancer Res. 2016 Dec 1;22(23):5755-5764. Epub 2016 May 16.

12.

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.

Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A, Migliaccio I.

Oncotarget. 2016 Sep 13;7(42):68012-68022. doi: 10.18632/oncotarget.12010.

13.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

14.

A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer.

Turner N, Forcato M, Nuzzo S, Malorni L, Bicciato S, Di Leo A.

NPJ Breast Cancer. 2015 Jun 2;1:15003. doi: 10.1038/npjbcancer.2015.3. eCollection 2015.

15.

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.

Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Di Leo A.

Nat Rev Clin Oncol. 2015 Sep;12(9):541-52. doi: 10.1038/nrclinonc.2015.99. Epub 2015 May 26. Review.

PMID:
26011489
16.

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.

Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A.

BMC Med. 2015 Mar 5;13:46. doi: 10.1186/s12916-015-0280-0. Review.

17.

New approaches for improving outcomes in breast cancer in Europe.

Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M.

Breast. 2015 Aug;24(4):321-30. doi: 10.1016/j.breast.2015.03.001. Epub 2015 Mar 31. Review.

18.

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.

Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, Pazzagli M, Di Leo A, Pinzani P.

Mol Oncol. 2015 Apr;9(4):749-57. doi: 10.1016/j.molonc.2014.12.001. Epub 2014 Dec 9.

19.

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.

Migliaccio I, Di Leo A, Malorni L.

Curr Opin Oncol. 2014 Nov;26(6):568-75. doi: 10.1097/CCO.0000000000000129. Review.

PMID:
25188473
20.

Use of solid-phase microextraction coupled to gas chromatography-mass spectrometry for determination of urinary volatile organic compounds in autistic children compared with healthy controls.

Cozzolino R, De Magistris L, Saggese P, Stocchero M, Martignetti A, Di Stasio M, Malorni A, Marotta R, Boscaino F, Malorni L.

Anal Bioanal Chem. 2014 Jul;406(19):4649-62. doi: 10.1007/s00216-014-7855-z. Epub 2014 May 15.

PMID:
24828982
21.

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A.

Cancers (Basel). 2014 Mar 25;6(2):684-707. doi: 10.3390/cancers6020684.

22.

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M.

J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.

23.

An integrated approach based on multiplexed protein array and iTRAQ labeling for in-depth identification of pathways associated to IVF outcome.

Severino V, Malorni L, Cicatiello AE, D'Esposito V, Longobardi S, Colacurci N, Miraglia N, Sannolo N, Farina A, Chambery A.

PLoS One. 2013 Oct 16;8(10):e77303. doi: 10.1371/journal.pone.0077303. eCollection 2013.

24.

The continued evidence from overviews: what is the clinical utility?

Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A.

Breast. 2013 Aug;22 Suppl 2:S8-11. doi: 10.1016/j.breast.2013.07.002. Review.

PMID:
24074798
25.

Adjuvant chemotherapy: which patient? What regimen?

Turner N, Biganzoli L, Malorni L, Migliaccio I, Moretti E, Pestrin M, Sanna G, Siclari O, Di Leo A.

Am Soc Clin Oncol Educ Book. 2013:3-8. doi: 10.1200/EdBook_AM.2013.33.3.

26.

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.

Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G.

Breast Cancer Res Treat. 2012 Dec;136(3):795-804. doi: 10.1007/s10549-012-2315-y. Epub 2012 Nov 4.

27.

Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.

Di Leo A, Malorni L.

J Clin Oncol. 2012 Jun 1;30(16):1897-900. doi: 10.1200/JCO.2012.41.7394. Epub 2012 Apr 30. No abstract available.

PMID:
22547606
28.

Proteomic profiling of human melanoma metastatic cell line secretomes.

Rocco M, Malorni L, Cozzolino R, Palmieri G, Rozzo C, Manca A, Parente A, Chambery A.

J Proteome Res. 2011 Oct 7;10(10):4703-14. doi: 10.1021/pr200511f. Epub 2011 Aug 22.

PMID:
21815687
29.

A Bowman-Birk inhibitor with anti-elastase activity from Lathyrus sativus L. seeds.

Rocco M, Malorni L, Chambery A, Poerio E, Parente A, Di Maro A.

Mol Biosyst. 2011 Aug;7(8):2500-7. doi: 10.1039/c1mb05141e. Epub 2011 Jun 7.

PMID:
21647515
30.

Purification and enzymatic properties of a peroxidase from leaves of Phytolacca dioica L. (Ombú tree).

Guida V, Criscuolo G, Tamburino R, Malorni L, Parente A, Di Maro A.

BMB Rep. 2011 Jan;44(1):64-9. doi: 10.5483/BMBRep.2011.44.1.64.

31.

Proteomic analysis of human U937 cell line activation mediated by Haemophilus influenzae type b P2 porin and its surface-exposed loop 7.

Severino V, Chambery A, Vitiello M, Cantisani M, Galdiero S, Galdiero M, Malorni L, Di Maro A, Parente A.

J Proteome Res. 2010 Feb 5;9(2):1050-62. doi: 10.1021/pr900931n.

PMID:
20043682
32.

Study of the fragmentation pattern of ketamine-heptafluorobutyramide by gas chromatography/electron ionization mass spectrometry.

Pieri M, Castiglia L, Miraglia N, Guadagni R, Malorni L, Sannolo N, Acampora A, Della Casa E.

Rapid Commun Mass Spectrom. 2010 Jan;24(1):49-56. doi: 10.1002/rcm.4357.

PMID:
19957293
33.

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.

Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H, Lee AV.

Breast Cancer Res Treat. 2010 Oct;123(3):651-60. doi: 10.1007/s10549-009-0632-6. Epub 2009 Nov 19.

34.

Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis.

Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, Blandino G, Gallucci M, Lauria R, Malorni L, Muti P.

J Exp Clin Cancer Res. 2009 Oct 8;28:135. doi: 10.1186/1756-9966-28-135.

35.

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.

Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404.

36.

Coupling immunomagnetic separation on magnetic beads with matrix-assisted laser desorption ionization-time of flight mass spectrometry for detection of staphylococcal enterotoxin B.

Schlosser G, Kacer P, Kuzma M, Szilágyi Z, Sorrentino A, Manzo C, Pizzano R, Malorni L, Pocsfalvi G.

Appl Environ Microbiol. 2007 Nov;73(21):6945-52. Epub 2007 Sep 7.

37.

Identification of phosphoproteins and determination of phosphorylation sites by zirconium dioxide enrichment and SELDI-MS/MS.

Cuccurullo M, Schlosser G, Cacace G, Malorni L, Pocsfalvi G.

J Mass Spectrom. 2007 Aug;42(8):1069-78.

PMID:
17610310
38.

Proteomic analysis of MCF-7 breast cancer cell line exposed to mitogenic concentration of 17beta-estradiol.

Malorni L, Cacace G, Cuccurullo M, Pocsfalvi G, Chambery A, Farina A, Di Maro A, Parente A, Malorni A.

Proteomics. 2006 Nov;6(22):5973-82.

PMID:
17051647
39.

Proteomic analysis of MCF-7 cell lines expressing the zinc-finger or the proline-rich domain of retinoblastoma-interacting-zinc-finger protein.

Chambery A, Farina A, Di Maro A, Rossi M, Abbondanza C, Moncharmont B, Malorni L, Cacace G, Pocsfalvi G, Malorni A, Parente A.

J Proteome Res. 2006 May;5(5):1176-85.

PMID:
16674107
40.

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.

Clin Cancer Res. 2005 Jul 1;11(13):4741-8.

41.

RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.

De Falco V, Guarino V, Malorni L, Cirafici AM, Troglio F, Erreni M, Pelicci G, Santoro M, Melillo RM.

Oncogene. 2005 Sep 15;24(41):6303-13.

PMID:
15940252
42.

Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.

De Laurentiis M, Cancello G, Zinno L, Montagna E, Malorni L, Esposito A, Pennacchio R, Silvestro L, Giuliano M, Giordano A, Caputo F, Accurso A, De Placido S.

Ann Oncol. 2005 May;16 Suppl 4:iv7-13. Review.

PMID:
15923434
43.

Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.

Castellone MD, Cirafici AM, De Vita G, De Falco V, Malorni L, Tallini G, Fagin JA, Fusco A, Melillo RM, Santoro M.

Oncogene. 2003 Jan 16;22(2):246-55.

PMID:
12527893
44.

A novel mass spectrometric technique for the evaluation of occupational exposure to methyl bromide.

Miraglia N, Genovese G, Acampora A, Malorni L, Sannolo N.

J Mass Spectrom. 2002 Nov;37(11):1171-4. No abstract available.

PMID:
12447896
45.

Ion trap mass spectrometry in the structural analysis of haemoglobin peptides modified by epichlorohydrin and diepoxybutane.

Miraglia N, Basile A, Pieri M, Acampora A, Malorni L, De Giulio B, Sannolo N.

Rapid Commun Mass Spectrom. 2002;16(9):840-7.

PMID:
11948814

Supplemental Content

Loading ...
Support Center